查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1474876

失智症治療市場規模、佔有率、趨勢分析報告：按適應症、藥物類別、途徑、分銷管道、地區、細分市場預測，2024-2030

Dementia Treatment Market Size, Share & Trends Analysis Report By Indication (Alzheimer's Disease Dementia, Vascular Dementia), By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

失智症治療市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球失智症治療市場規模將達到281.1億美元，2024年至2030年複合年成長率為7.68%。

失智症患者數量的增加、新藥的推出以及市場相關人員和研究機構擴大參與開發有效的治療方法是推動市場成長的一些關鍵因素。根據 Cross River Therapy 2023 年 9 月發布的資料，英國阿茲海默症（AD）盛行率約為每 10 萬人 42.70 人，使其成為人均患者數第二高的國家。

政府和非政府組織為支持失智症治療認知宣傳活動和開發新治療方法的研究活動而採取的有利舉措的增加預計將推動市場成長。例如，2022年2月，麥吉爾大學的失智症教育計畫獲得了加拿大公共衛生局的資助，並啟動了15個計劃，以提高人們對該疾病的認知。失智症社區投資 (DCI) 將投資 758,430 美元，支持該大學為成人學習者提供為期 10 週（總計）的 10 個線上數位學習，以傳播看護者的認知。

學術研究機構也從事研究活動，例如研究不同類型的失智症和開發有效的治療方法以減輕整體疾病負擔。例如，2024 年 2 月，科羅拉多大學安舒茨醫學校區的研究人員發現 Mdm2 蛋白和在臨床實驗癌症藥物 Nutlin 可以預防與阿茲海默症。此外，2023 年 12 月，賓州大學佩雷爾曼醫學院的臨床前研究表明，Chaperone分子規定的特定蛋白質可以逆轉大腦老化和疾病（包括記憶喪失）的徵兆。

新興市場參與者正在與區域參與者和研究機構合作，以提高開發有效和安全的失智症治療方法的能力。 2021 年 2 月，Exscientia 與牛津大學合作開發阿茲海默症的治療方法。此外，Eisai和百健（Biogen）合作快速開發失智症的有效治療方法。這些公司共同開發了 aducanumab 和 lecanemab。兩家公司的這些藥物均已獲得全球主要監管機構的市場核准。

失智症治療市場報告亮點

  • 由於AD失智症的高盛行率和認證核可藥，AD失智症在適應症細分市場中佔據主導地位，2023年佔有率為60.11%。
  • 由於發病率和嚴重程度不斷增加，路易氏體失智症(LBD) 領域預計從 2024 年到 2030 年將以最快的複合年成長率成長。
  • 由於口服和經皮吸收貼片的處方率較高，膽鹼酯酶抑制劑細分市場在 2023 年佔據最大佔有率。
  • 由於組合藥物組合藥物領域的複合年成長率將達到最快。
  • 由於生物製藥的引入和有前景的注射藥物管道的存在，預計注射藥物給藥途徑部分將在 2024 年至 2030 年實現最快的複合年成長率。
  • 由於該地區疾病盛行率高、市場參與者強大以及報銷政策更好等因素，2023年全球市場將由北美主導。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章失智症治療市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 失智症治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章失智症治療市場：適應症估計與趨勢分析

  • 全球失智症治療市場：適應症儀表板
  • 全球失智症治療市場：適應症變化分析
  • 全球失智症治療市場：按適應症、收益2018-2030 年
  • 阿茲海默症失智症
  • 血管性失智症
  • 路易氏體失智症
  • 額顳葉型失智症（FTD）
  • 帕金森氏症失智症
  • 其他

第5章失智症治療市場：藥物類別估計和趨勢分析

  • 全球失智症治療市場：藥物類別儀表板
  • 全球失智症治療市場：藥物類別波動分析
  • 全球失智症治療市場，依藥物類別，收益2018-2030
  • 膽鹼酯酶抑制劑
  • NMDA受體拮抗劑
  • 單胺氧化酶抑制劑
  • 伴隨藥物
  • 其他

第6章失智症治療市場：給藥途徑預估及趨勢分析

  • 全球失智症治療市場：途徑途徑儀表板
  • 全球失智症治療市場：給藥途徑變化分析
  • 全球失智症治療市場：依途徑、2018-2030 年收益
  • 口服
  • 經皮吸收貼片
  • 注射

第7章失智症治療市場：通路估算及趨勢分析

  • 全球失智症治療市場：分銷通路儀表板
  • 全球失智症治療市場：分銷管道波動分析
  • 全球失智症治療市場：按分銷管道分類，2018-2030 年收益
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章失智症治療市場：區域估計和趨勢分析

  • 區域儀表板
  • 市場規模、預測/趨勢分析，2018-2030
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第9章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • Eisai Co., Ltd.
    • Lilly
    • Novartis AG
    • DAIICHI SANKYO COMPANY, LIMITED
    • AbbVie Inc.
    • H. Lundbeck A/S
    • Biogen
    • Cipla Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Viatris Inc.
Product Code: GVR-4-68040-258-5

Dementia Treatment Market Growth & Trends:

The global dementia treatment market size is anticipated to reach USD 28.11 billion by 2030, registering a CAGR of 7.68% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing patient base of dementia, introduction of novel drugs, and increasing involvement of market players and research institutes to develop effective treatment for the disease are some of key factors driving market growth. According to the Cross River Therapy data published in September 2023, the prevalence of Alzheimer's disease (AD) in the UK is around 42.70 cases per 100,000 people, which makes it the country with the second-greatest number of cases per capita.

Increasing favorable initiatives undertaken by government and non-government bodies to support the awareness campaign and research activities to develop novel therapies for dementia treatment are anticipated to fuel market growth. For instance, in February 2022, McGill University's Dementia Education Program initiated 15 projects funded by the Public Health Agency of Canada to increase awareness about the disease. The Dementia Community Investment (DCI) is going to invest USD 758,430 to support the University's Ten Online Modules over Ten Weeks for Adult Learners (TOTAL) eLearning to spread awareness among caregivers.

Academic and research institutes are further involved in research activities to study different types of dementia and development of effective therapeutics to reduce the overall disease burden. For instance, in February 2024, researchers at the University of Colorado Anschutz Medical Campus found that Mdm2 protein with an investigational cancer drug, nutlin, can prevent the destruction of synapses and dendritic spines associated with Alzheimer's disease. Moreover, in December 2023, A preclinical study from the Perelman School of Medicine at the University of Pennsylvania showed that a chaperone molecule formulated specific proteins that can reverse disease signs including aging brain and memory impairment.

Market players are collaborating with regional players and research institutions to increase their capabilities to develop effective and safe therapy for dementia. In February 2021, Exscientia and the University of Oxford tied up to develop therapies for Alzheimer's disease. Moreover, Eisai Co., Ltd. and Biogen partnered to develop effective therapies for dementia earlier. These companies have jointly developed aducanumab and lecanemab. The companies are receiving market approvals for these drugs from key regulatory authorities across the globe.

Dementia Treatment Market Report Highlights:

  • The AD dementia segment dominated the indication segment market with a share of 60.11% in 2023 owing to a high prevalence of AD dementia and approved drugs
  • The Lewy body dementia (LBD) segment is expected to grow at the fastest CAGR from 2024 to 2030 owing to the increasing incidence and severity of the disease
  • The cholinesterase inhibitors segment held the largest share in 2023 owing to high prescription rate of oral and transdermal patches of these drugs
  • The combination drug segment is projected to experience the fastest CAGR from 2024 to 2030 owing to increased effectiveness and adoption of combination drugs
  • The injectables route of administration segment is anticipated to register the fastest CAGR from 2024 to 2030 owing to the introduction of biological drugs and the presence of promising injectable drugs in the pipeline
  • North America dominated the global market in 2023 owing to factors, such as high disease prevalence, presence of strong market players, and better reimbursement policies in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Drug Class
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Indication and drug class outlook
    • 2.2.2. Route of administration and distribution channel outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Dementia Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of dementia
      • 3.2.1.2. Increasing government funding and awareness programs
      • 3.2.1.3. Surge in R&D activities
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High failure rates of drugs at approval stages
  • 3.3. Dementia Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Dementia Treatment Market: Indication Estimates & Trend Analysis

  • 4.1. Global Dementia Treatment Market: Indication Dashboard
  • 4.2. Global Dementia Treatment Market: Indication Movement Analysis
  • 4.3. Global Dementia Treatment Market by Indication, Revenue 2018 - 2030 (USD Million)
  • 4.4. Alzheimer's Disease Dementia
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Vascular Dementia
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Lewy Body Dementia
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Frontotemporal Dementia (FTD)
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Parkinson's Disease Dementia
    • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Dementia Treatment Market: Drug Class Estimates & Trend Analysis

  • 5.1. Global Dementia Treatment Market: Drug Class Dashboard
  • 5.2. Global Dementia Treatment Market: Drug Class Movement Analysis
  • 5.3. Global Dementia Treatment Market by Drug Class, Revenue 2018 - 2030 (USD Million)
  • 5.4. Cholinesterase Inhibitors
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. NMDA Receptor Antagonist
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. MAO Inhibitors
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Combination Drug
    • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Dementia Treatment Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Global Dementia Treatment Market: Route of Administration Dashboard
  • 6.2. Global Dementia Treatment Market: Route of Administration Movement Analysis
  • 6.3. Global Dementia Treatment Market by Route of Administration, Revenue 2018 - 2030 (USD Million)
  • 6.4. Oral
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Transdermal Patch
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Injectable
    • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Dementia Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Global Dementia Treatment Market: Distribution Channel Dashboard
  • 7.2. Global Dementia Treatment Market: Distribution Channel Movement Analysis
  • 7.3. Global Dementia Treatment Market by Distribution Channel, Revenue 2018 - 2030 (USD Million)
  • 7.4. Hospital Pharmacy
    • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Retail Pharmacy
    • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Online Pharmacy
    • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Dementia Treatment Market: Regional Estimates & Trend Analysis by Indication, Drug Class, Route of Administration, and Distribution Channel

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Mexico
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. Argentina
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2023
    • 9.3.4. Eisai Co., Ltd.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Lilly
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Novartis AG
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. DAIICHI SANKYO COMPANY, LIMITED
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. AbbVie Inc.
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. H. Lundbeck A/S
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Biogen
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Cipla Inc.
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Sun Pharmaceutical Industries Ltd.
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Viatris Inc.
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America dementia treatment market, by country, 2018 - 2030 (USD Million)
  • Table 3 North America dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 4 North America dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 North America dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 6 North America dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 U.S. dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 8 U.S. dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 9 U.S. dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 10 U.S. dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 Canada dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 12 Canada dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 13 Canada dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 14 Canada dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Europe dementia treatment market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 17 Europe dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 18 Europe dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 19 Europe dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Germany dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 21 Germany dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 22 Germany dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 23 Germany dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 UK dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 25 UK dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 26 UK dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 27 UK dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 France dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 29 France dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 30 France dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 31 France dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 32 Italy dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 33 Italy dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 34 Italy dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 35 Italy dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36 Spain dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 37 Spain dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Spain dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 Spain dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 40 Denmark dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 41 Denmark dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 Denmark dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Denmark dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 44 Sweden dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 45 Sweden dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 46 Sweden dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 47 Sweden dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48 Norway dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 49 Norway dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 50 Norway dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 51 Norway dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 Asia Pacific dementia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 53 Asia Pacific dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 54 Asia Pacific dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 55 Aisa Pacific dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 56 Aisa Pacific dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57 China dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 58 China dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 59 China dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 60 China dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Japan dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 62 Japan dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 63 Japan dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 64 Japan dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65 India dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 66 India dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 67 India dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 68 India dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 69 South Korea dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 70 South Korea dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 71 South Korea dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 72 South Korea dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 73 Australia dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 74 Australia dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 75 Australia dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 76 Australia dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77 Thailand dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 78 Thailand dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 79 Thailand dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 80 Thailand dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 81 Latin America dementia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 82 Latin America dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 83 Latin America dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 84 Latin America dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 85 Latin America dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 86 Brazil dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 87 Brazil dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 88 Brazil dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 89 Brazil dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 Mexico dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 91 Mexico dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 92 Mexico dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 93 Mexico dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 94 Argentina dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 95 Argentina dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 96 Argentina dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 97 Argentina dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 98 MEA dementia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 99 MEA dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 100 MEA dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 101 MEA dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 102 MEA dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 103 South Africa dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 104 South Africa dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 105 South Africa dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 106 South Africa dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 111 UAE dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 112 UAE dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 113 UAE dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 114 UAE dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 115 Kuwait dementia treatment market, by indication, 2018 - 2030 (USD Million)
  • Table 116 Kuwait dementia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 117 Kuwait dementia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 118 Kuwait dementia treatment market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Dementia treatment market: market outlook
  • Fig. 14 Dementia treatment competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Dementia treatment market driver impact
  • Fig. 18 Dementia treatment market restraint impact
  • Fig. 19 Dementia treatment market: Indication movement analysis
  • Fig. 20 Dementia treatment market: Indication outlook and key takeaways
  • Fig. 21 Alzheimer's disease dementia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Vascular dementia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Lewy body dementia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Frontotemporal dementia (FTD) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Parkinson'skinson disease dementia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Dementia treatment market: Drug class movement analysis
  • Fig. 28 Dementia treatment market: Drug class outlook and key takeaways
  • Fig. 29 Cholinesterase inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 NMDA receptor antagonist market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 MAO inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Combination drug market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Dementia treatment market: Route of administration movement analysis
  • Fig. 35 Dementia treatment market: Route of administration outlook and key takeaways
  • Fig. 36 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Transdermal patch market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Dementia treatment market: Distribution channel movement analysis
  • Fig. 40 Dementia treatment market: Distribution channel outlook and key takeaways
  • Fig. 41 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Global dementia treatment market: Regional movement analysis
  • Fig. 45 Global dementia treatment market: Regional outlook and key takeaways
  • Fig. 46 Global dementia treatment market share and leading players
  • Fig. 47 North America, by country
  • Fig. 48 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 U.S. key country dynamics
  • Fig. 50 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Canada key country dynamics
  • Fig. 52 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 UK key country dynamics
  • Fig. 55 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Germany key country dynamics
  • Fig. 57 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 France key country dynamics
  • Fig. 59 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Italy key country dynamics
  • Fig. 61 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Spain key country dynamics
  • Fig. 63 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Denmark key country dynamics
  • Fig. 65 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Sweden key country dynamics
  • Fig. 67 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Norway key country dynamics
  • Fig. 69 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 China key country dynamics
  • Fig. 72 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Japan key country dynamics
  • Fig. 74 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 India key country dynamics
  • Fig. 76 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Thailand key country dynamics
  • Fig. 78 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 South Korea key country dynamics
  • Fig. 80 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Australia key country dynamics
  • Fig. 82 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Brazil key country dynamics
  • Fig. 85 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Mexico key country dynamics
  • Fig. 87 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Argentina key country dynamics
  • Fig. 89 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 South Africa key country dynamics
  • Fig. 92 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Saudi Arabia key country dynamics
  • Fig. 94 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 UAE key country dynamics
  • Fig. 96 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Kuwait key country dynamics
  • Fig. 98 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Market share of key market players- 2023